Liver International,
Год журнала:
2023,
Номер
43(6), С. 1170 - 1182
Опубликована: Апрель 5, 2023
Hepatocytic
ballooning
is
a
key
histological
feature
in
the
diagnosis
of
non-alcoholic
steatohepatitis
(NASH)
and
an
essential
component
two
most
widely
used
scoring
systems
for
diagnosing
staging
fatty
liver
disease
(NAFLD)
[namely,
NAFLD
activity
score
(NAS),
steatosis,
fibrosis
(SAF)
system].
As
result
increasing
incidence
NASH
globally,
diagnostic
challenges
hepatocytic
are
unprecedented.
Despite
clear
pathological
concept
ballooning,
there
still
assessing
'real
life'
situations.
can
be
confused
with
cellular
oedema
microvesicular
steatosis.
Significant
inter-observer
variability
does
exist
presence
severity
ballooning.
In
this
review
article,
we
describe
underlying
mechanisms
associated
Specifically,
discuss
increased
endoplasmic
reticulum
stress
unfolded
protein
response,
as
well
rearrangement
intermediate
filament
cytoskeleton,
appearance
Mallory-Denk
bodies
activation
sonic
Hedgehog
pathway.
We
also
use
artificial
intelligence
detection
interpretation
which
may
provide
new
possibilities
future
treatment.
Hepatology Communications,
Год журнала:
2024,
Номер
8(7)
Опубликована: Июль 1, 2024
With
an
increasing
prevalence,
metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD)
has
become
a
major
global
health
problem.
MASLD
is
well-known
as
multifactorial
disease.
Mitochondrial
dysfunction
and
alterations
in
the
gut
bacteria
are
2
vital
events
MASLD.
Recent
studies
have
highlighted
cross-talk
between
microbiota
mitochondria,
mitochondria
recognized
pivotal
targets
of
to
modulate
host's
physiological
state.
plays
role
associated
with
multiple
pathological
changes,
including
hepatocyte
steatosis,
oxidative
stress,
inflammation,
fibrosis.
Metabolites
crucial
mediators
that
influence
extraintestinal
organs.
Additionally,
regulation
composition
may
serve
promising
therapeutic
strategy
for
This
study
reviewed
potential
roles
several
common
metabolites
MASLD,
emphasizing
their
impact
on
mitochondrial
function.
Finally,
we
discuss
current
treatments
probiotics,
prebiotics,
antibiotics,
fecal
transplantation.
These
methods
concentrate
restoring
promote
host
health.
Journal of Hepatology,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 1, 2025
The
liver
acts
as
a
central
metabolic
hub,
integrating
signals
from
the
gastrointestinal
tract
and
adipose
tissue
to
regulate
carbohydrate,
lipid,
amino
acid
metabolism.
Gut-derived
metabolites,
such
acetate
ethanol
non-esterified
fatty
acids
white
(WAT),
influence
hepatic
processes,
which
rely
on
mitochondrial
function
maintain
systemic
energy
balance.
Metabolic
dysregulation
obesity,
insulin
resistance,
type
2
diabetes
disrupt
these
pathways,
leading
dysfunction-associated
steatotic
disease
(MASLD)
steatohepatitis
(MASH).
This
review
explores
fluxes
within
gut-adipose
tissue-liver
axis,
focusing
pivotal
role
of
de
novo
lipogenesis
(DNL),
dietary
substrates
like
glucose
fructose,
changes
in
during
MASLD
progression.
It
highlights
contributions
resistance
impaired
dynamics
lipid
accumulation.
Further
understanding
how
interplay
between
substrate
flux
gastro-intestinal
integrates
with
intersects
structural
functional
alterations
mitochondria
will
be
important
identify
novel
therapeutic
targets
advance
treatment
MASH.
Cell Metabolism,
Год журнала:
2023,
Номер
35(11), С. 1887 - 1896.e5
Опубликована: Окт. 30, 2023
The
PNPLA3
I148M
variant
is
the
major
genetic
risk
factor
for
all
stages
of
fatty
liver
disease,
but
underlying
pathophysiology
remains
unclear.
We
studied
effect
this
on
hepatic
metabolism
in
homozygous
carriers
and
non-carriers
under
multiple
physiological
conditions
with
state-of-the-art
stable
isotope
techniques.
After
an
overnight
fast,
had
higher
plasma
β-hydroxybutyrate
concentrations
lower
de
novo
lipogenesis
(DNL)
compared
to
non-carriers.
a
mixed
meal,
acids
were
channeled
toward
ketogenesis
carriers,
which
was
associated
increase
mitochondrial
redox
state.
During
ketogenic
diet,
manifested
increased
rates
intrahepatic
lipolysis,
concentrations,
decreased
citrate
synthase
flux.
These
studies
demonstrate
that
have
dysfunction
leading
reduced
DNL
channeling
carbons
ketogenesis.
findings
implications
understanding
why
predisposes
progressive
disease.
Genes & Diseases,
Год журнала:
2023,
Номер
11(3), С. 101115 - 101115
Опубликована: Сен. 17, 2023
The
liver
is
an
important
metabolic
and
detoxification
organ
hence
demands
a
large
amount
of
energy,
which
mainly
produced
by
the
mitochondria.
Liver
tissues
patients
with
alcohol-related
or
non-alcohol-related
diseases
contain
ultrastructural
mitochondrial
lesions,
DNA
damage,
disturbed
dynamics,
compromised
ATP
production.
Overproduction
reactive
oxygen
species
induces
oxidative
damage
to
proteins
DNA,
decreases
membrane
potential,
triggers
hepatocyte
inflammation,
promotes
programmed
cell
death,
all
impair
function.
Mitochondrial
may
be
potential
novel
non-invasive
biomarker
risk
progression
cirrhosis
hepatocellular
carcinoma
in
infected
hepatitis
B
virus.
We
herein
present
review
mechanisms
dysfunction
development
acute
injury
chronic
diseases,
such
as
carcinoma,
viral
hepatitis,
drug-induced
injury,
alcoholic
disease,
non-alcoholic
fatty
disease.
This
also
discusses
mitochondrion-centric
therapies
for
treating
diseases.
Metabolites,
Год журнала:
2023,
Номер
14(1), С. 12 - 12
Опубликована: Дек. 23, 2023
Metabolic-associated
steatotic
liver
disease
(MASLD)
is
a
cluster
of
pathological
conditions
primarily
developed
due
to
the
accumulation
ectopic
fat
in
hepatocytes.
During
severe
form
disease,
i.e.,
metabolic-associated
steatohepatitis
(MASH),
accumulated
lipids
promote
lipotoxicity,
resulting
cellular
inflammation,
oxidative
stress,
and
hepatocellular
ballooning.
If
left
untreated,
advanced
progresses
fibrosis
tissue,
irreversible
hepatic
cirrhosis
or
development
carcinoma.
Although
numerous
mechanisms
have
been
identified
as
significant
contributors
advancement
MASLD,
altered
lipid
metabolism
continues
stand
out
major
factor
contributing
disease.
This
paper
briefly
discusses
dysregulation
during
various
stages
MASLD.
Annual Review of Nutrition,
Год журнала:
2023,
Номер
43(1), С. 199 - 223
Опубликована: Май 19, 2023
Nonalcoholic
fatty
liver
disease
(NAFLD)
is
the
most
common
chronic
worldwide,
particularly
in
obese
and
type
2
diabetic
individuals.
Currently,
there
are
no
therapies
for
NAFLD
that
have
been
approved
by
US
Food
Drug
Administration.
Herein,
we
examine
rationale
using
ω3
polyunsaturated
acids
(PUFAs)
therapy.
This
focus
based
on
finding
severity
associated
with
a
reduction
of
hepatic
C20-22
PUFAs.
Because
PUFAs
pleiotropic
regulators
cell
function,
loss
has
potential
to
significantly
impact
function.
We
describe
prevalence
pathophysiology
as
well
current
therapies.
also
present
evidence
from
clinical
preclinical
studies
evaluated
capacity
treat
NAFLD.
Given
evidence,
dietary
PUFA
supplementation
decrease
human
reducing
hepatosteatosis
injury.
